Tema Etfs LLC Acquires New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Tema Etfs LLC acquired a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,811 shares of the company's stock, valued at approximately $1,113,000.

Several other institutional investors have also recently made changes to their positions in the stock. Sphera Funds Management LTD. acquired a new position in shares of SpringWorks Therapeutics during the fourth quarter valued at about $3,613,000. ProShare Advisors LLC increased its position in shares of SpringWorks Therapeutics by 31.7% during the fourth quarter. ProShare Advisors LLC now owns 22,883 shares of the company's stock worth $827,000 after acquiring an additional 5,503 shares in the last quarter. Patient Square Capital LP bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth about $3,365,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of SpringWorks Therapeutics by 2.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,013 shares of the company's stock worth $1,591,000 after acquiring an additional 931 shares in the last quarter. Finally, Integral Health Asset Management LLC bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth about $3,613,000.

Insider Activity

In related news, CEO Saqib Islam sold 49,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $54.24, for a total value of $2,657,760.00. Following the completion of the transaction, the chief executive officer now directly owns 954,869 shares in the company, valued at approximately $51,792,094.56. The trade was a 4.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Bhavesh Ashar sold 1,016 shares of SpringWorks Therapeutics stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $61.19, for a total transaction of $62,169.04. Following the completion of the transaction, the insider now owns 62,053 shares of the company's stock, valued at $3,797,023.07. This represents a 1.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 146,944 shares of company stock valued at $8,439,479 in the last three months. Company insiders own 7.83% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. HC Wainwright reissued a "neutral" rating and set a $47.00 target price (down from $74.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, April 30th. Evercore ISI downgraded shares of SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Cowen downgraded shares of SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday, April 29th. Guggenheim reiterated a "neutral" rating and issued a $47.00 price objective on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. Finally, Wedbush reiterated a "neutral" rating and issued a $47.00 price objective (down previously from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, SpringWorks Therapeutics currently has an average rating of "Hold" and a consensus target price of $52.57.

SpringWorks Therapeutics Price Performance

Shares of SpringWorks Therapeutics stock traded up $0.04 on Tuesday, reaching $46.31. 2,884,370 shares of the company traded hands, compared to its average volume of 2,116,100. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00. The company has a 50 day moving average of $43.79 and a 200 day moving average of $42.46. The firm has a market capitalization of $3.49 billion, a PE ratio of -13.31 and a beta of 0.77.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The company had revenue of $49.09 million for the quarter, compared to the consensus estimate of $64.19 million. As a group, analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.